Denali Therapeutics Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Denali Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $205.33 million for the year ending 2025.

  • Denali Therapeutics Inc. showed an increase of +17.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 10 years of available data (2016 to 2025), Denali Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 415.2%.
  • Historical annual values: Fiscal year 2025: $205.33 million | Fiscal year 2024: $174.96 million | Fiscal year 2023: $127.11 million | Fiscal year 2022: $218.04 million | Fiscal year 2021: $293.48 million | Fiscal year 2020: $507.14 million | Fiscal year 2019: $79.45 million | Fiscal year 2018: $77.12 million | Fiscal year 2017: $218.38 million | Fiscal year 2016: $39.85 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: